Actinium Pharmaceuticals Inc - Asset Resilience Ratio
Actinium Pharmaceuticals Inc (ATNM) has an Asset Resilience Ratio of 0.25% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Actinium Pharmaceuticals Inc (ATNM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2016)
This chart shows how Actinium Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Actinium Pharmaceuticals Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Actinium Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Actinium Pharmaceuticals Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.00K | 0.25% |
| Total Liquid Assets | $40.00K | 0.25% |
Asset Resilience Insights
- Limited Liquidity: Actinium Pharmaceuticals Inc maintains only 0.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Actinium Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Actinium Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Actinium Pharmaceuticals Inc (2014–2016)
The table below shows the annual Asset Resilience Ratio data for Actinium Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.16% | $35.00K | $22.53 Million | +0.02pp |
| 2015-12-31 | 0.13% | $35.00K | $26.59 Million | -0.02pp |
| 2014-12-31 | 0.15% | $11.35K | $7.57 Million | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more